Sanofi buys hep B vaccine maker for $2.2bn [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
The transaction, for a price of $15.50 per share in cash, is expected to close in the first quarter of 2026. Through the deal, Sanofi will acquire Dynavax's hepatitis B vaccine HEPLISAV-B. The product won approval in the US and Europe in 2017 and 2021, respectively. Sanofi does not currently have a hepatitis B vaccine in its portfolio. The French drugmaker previously won approval for a hepatitis B vaccine in a joint venture with MSD, though the latter company now commercialises the jab, which is known under the HBVaxPro and Recombivax HB brand names in Europe and the US, respectively. Heplisav-B is administered via a two-dose regimen delivered within one month, unlike GSK's Engerix-B and MSD's Recombivax HB. These rival products are given in three doses over six months. With the Dynavax acquisition, Sanofi is adding a strong revenue avenue for the virus that causes serious liver infection. HEPLISAV-B generated sales of $268.4m in 2024, with Dynavax forecasting net product reven
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA [Yahoo! Finance]Yahoo! Finance
- Sanofi Agrees to Buy Dynavax for $2.2 Billion After FDA MS Drug Rejection [Yahoo! Finance]Yahoo! Finance
- Delayed MS Decision and Trial Miss Add to Sanofi's R&D Challenges [Yahoo! Finance]Yahoo! Finance
- Honoring 45 Organ, Eye and Tissue Donors, Living Donors and Recipients: The 2026 OneLegacy Donate Life Rose Parade® Float Celebrates 23 Years of Participation in the Iconic Rose Parade® [Yahoo! Finance]Yahoo! Finance
- Sanofi to Buy Dynavax to Boost Vaccines Business [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 12/29/25 - Form 6-K
- 12/29/25 - Form 6-K
- 12/23/25 - Form 6-K
- SNY's page on the SEC website